Chemico-Biological Interactions, Год журнала: 2024, Номер 396, С. 111055 - 111055
Опубликована: Май 17, 2024
Язык: Английский
Healthcare, Год журнала: 2024, Номер 12(2), С. 125 - 125
Опубликована: Янв. 5, 2024
Artificial intelligence (AI) has emerged as a crucial tool in healthcare with the primary aim of improving patient outcomes and optimizing delivery. By harnessing machine learning algorithms, natural language processing, computer vision, AI enables analysis complex medical data. The integration into systems aims to support clinicians, personalize care, enhance population health, all while addressing challenges posed by rising costs limited resources. As subdivision science, focuses on development advanced algorithms capable performing tasks that were once reliant human intelligence. ultimate goal is achieve human-level performance improved efficiency accuracy problem-solving task execution, thereby reducing need for intervention. Various industries, including engineering, media/entertainment, finance, education, have already reaped significant benefits incorporating their operations. Notably, sector witnessed rapid growth utilization technology. Nevertheless, there remains untapped potential truly revolutionize industry. It important note despite concerns about job displacement, should not be viewed threat workers. Instead, are designed augment professionals, freeing up time focus more critical tasks. automating routine repetitive tasks, can alleviate burden allowing them dedicate attention care meaningful interactions. However, legal ethical must addressed when embracing technology medicine, alongside comprehensive public education ensure widespread acceptance.
Язык: Английский
Процитировано
140
Pharmaceutics, Год журнала: 2024, Номер 16(3), С. 332 - 332
Опубликована: Фев. 27, 2024
The landscape of medical treatments is undergoing a transformative shift. Precision medicine has ushered in revolutionary era healthcare by individualizing diagnostics and according to each patient’s uniquely evolving health status. This groundbreaking method tailoring disease prevention treatment considers individual variations genes, environments, lifestyles. goal precision target the “five rights”: right patient, drug, time, dose, route. In this pursuit, silico techniques have emerged as an anchor, driving forward making realistic promising avenue for personalized therapies. With advancements high-throughput DNA sequencing technologies, genomic data, including genetic variants their interactions with other environment, can be incorporated into clinical decision-making. Pharmacometrics, gathering pharmacokinetic (PK) pharmacodynamic (PD) mathematical models further contribute drug optimization, behavior prediction, drug–drug interaction identification. Digital health, wearables, computational tools offer continuous monitoring real-time data collection, enabling adjustments. Furthermore, incorporation extensive datasets tools, such electronic records (EHRs) omics also another pathway acquire meaningful information field. Although they are fairly new, machine learning (ML) algorithms artificial intelligence (AI) resources researchers use analyze big develop predictive models. review explores interplay these multiple approaches advancing fostering healthcare. Despite intrinsic challenges, ethical considerations, protection, need more comprehensive research, marks new patient-centered Innovative hold potential reshape future generations come.
Язык: Английский
Процитировано
102
Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)
Опубликована: Март 4, 2024
Abstract In the era of precision medicine, it has been increasingly recognized that individuals with a certain disease are complex and different from each other. Due to underestimation significant heterogeneity across participants in traditional “one-size-fits-all” trials, patient-centered trials could provide optimal therapy customization specific biomarkers were developed including basket, umbrella, platform trial designs under master protocol framework. recent years, successive FDA approval indications based on biomarker-guided demonstrated these new clinical ushering tremendous opportunities. Despite rapid increase number current research understanding designs, as compared remains limited. The majority focuses methodologies, there is lack in-depth insight concerning underlying biological logic designs. Therefore, we this comprehensive review discovery development their perspective medicine. Meanwhile, discuss future directions potential design view “Precision Pro”, “Dynamic Precision”, “Intelligent Precision”. This would assist trial-related researchers enhance innovation feasibility by expounding logic, which be essential accelerate progression
Язык: Английский
Процитировано
61
Pharmaceuticals, Год журнала: 2023, Номер 16(2), С. 253 - 253
Опубликована: Фев. 7, 2023
Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs speed up development process of anti-cancer designs become urgent question for pharmaceutical industry. Computer-aided methods have played major role in cancer treatments over three decades. Recently, artificial intelligence emerged powerful promising technology faster, cheaper, more effective designs. This study is narrative review that reviews wide range applications intelligence-based design. We further clarify fundamental principles these methods, along with their advantages disadvantages. Furthermore, we collate large number databases, including omics database, epigenomics chemical compound databases. Other researchers can consider them adapt own requirements.
Язык: Английский
Процитировано
55
Pharmaceuticals, Год журнала: 2023, Номер 16(4), С. 614 - 614
Опубликована: Апрель 19, 2023
(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by discovery druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies FDA-approved. (2) Methods: We performed a review literature reported trials that to approval ongoing clinical currently investigating novel biomarker-based approaches. (3) Results: discussed agnostic treatments: pembrolizumab dostarlimab for MMRd/MSI-H, TMB-H, larotrectinib entrectinib NTRK-fusions, dabrafenib plus trametinib BRAF V600E mutation, selpercatinib RET fusions. In addition, we approaches, including ALK, HER2, FGFR, NRG1. (4) Conclusions: Precision medicine is constantly evolving, improvement diagnostic tools allow wider genomic definition tumor, targeted promising treatment strategy tailored specific tumor profile, leading improved survival outcomes.
Язык: Английский
Процитировано
52
Drug Development Research, Год журнала: 2023, Номер 84(8), С. 1652 - 1663
Опубликована: Сен. 15, 2023
By harnessing artificial intelligence (AI) algorithms and machine learning techniques, the entire drug discovery process stands to undergo a profound transformation, offering myriad of advantages. Foremost among these is ability AI conduct swift efficient screenings expansive compound libraries, significantly augmenting identification potential candidates. Moreover, can prove instrumental in predicting efficacy safety profiles candidate compounds, thus endowing invaluable insights reducing reliance on extensive preclinical clinical testing. This predictive capacity has streamline development pipeline enhance success rate trials, ultimately resulting emergence more efficacious safer therapeutic agents. However, deployment introduces certain challenges that warrant attention. A primary hurdle entails imperative acquisition high-quality diverse data. Furthermore, ensuring interpretability models assumes critical importance securing regulatory endorsement cultivating trust within scientific medical communities. Addressing ethical considerations, including data privacy mitigating bias, represents an additional momentous challenge, requiring assiduous navigation. In this review, we provide intricate comprehensive overview multifaceted intrinsic conventional paradigms, while simultaneously interrogating effectively surmounting formidable obstacles.
Язык: Английский
Процитировано
46
Pharmacological Research, Год журнала: 2024, Номер 202, С. 107099 - 107099
Опубликована: Фев. 10, 2024
Cancer cells frequently develop resistance to chemotherapeutic therapies and targeted drugs, which has been a significant challenge in cancer management. With the growing advances technologies isolation identification of natural products, potential products combating multidrug received substantial attention. Importantly, can impact multiple targets, be valuable overcoming drug from different perspectives. In current review, we will describe well-established mechanisms underlying resistance, introduce that could target these resistant mechanisms. Specifically, discuss compounds such as curcumin, resveratrol, baicalein, chrysin more, their roles resistance. This review article aims provide systematic summary recent rationales for novel discovery.
Язык: Английский
Процитировано
32
Proteomes, Год журнала: 2024, Номер 12(3), С. 25 - 25
Опубликована: Сен. 6, 2024
High-throughput omics technologies have dramatically changed biological research, providing unprecedented insights into the complexity of living systems. This review presents a comprehensive examination current landscape high-throughput pipelines, covering key technologies, data integration techniques and their diverse applications. It looks at advances in next-generation sequencing, mass spectrometry microarray platforms highlights contribution to volume precision. In addition, this critical role bioinformatics tools statistical methods managing large datasets generated by these technologies. By integrating multi-omics data, researchers can gain holistic understanding systems, leading identification new biomarkers therapeutic targets, particularly complex diseases such as cancer. The also electronic health records (EHRs) potential for cloud computing big analytics improve storage, analysis sharing. Despite significant advances, there are still challenges complexity, technical limitations ethical issues. Future directions include development more sophisticated computational application advanced machine learning techniques, which addressing heterogeneity datasets. aims serve valuable resource practitioners, highlighting transformative advancing personalized medicine improving clinical outcomes.
Язык: Английский
Процитировано
26
CA A Cancer Journal for Clinicians, Год журнала: 2024, Номер 74(5), С. 433 - 452
Опубликована: Май 30, 2024
Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero specific genetic anomalies responsible for fueling malignant growth. The watershed moment tumor-agnostic arrived 2017, with US Food and Drug Administration's historic approval pembrolizumab, an immune checkpoint inhibitor. This milestone marked marriage genomics immunology fields, as immunotherapeutic agent gained genomic biomarkers, specifically, microsatellite instability-high mismatch repair deficiency (dMMR). Subsequently, NTRK inhibitors, designed to combat gene fusions prevalent various tumor types, including pediatric cancers adult solid tumors, further underscored potential therapies. Administration approvals targeted (BRAF V600E, RET fusion), immunotherapies (tumor mutational burden ≥10 mutations per megabase, dMMR) antibody-drug conjugate (Her2-positive-immunohistochemistry 3+ expression) pan-cancer efficacy have continued, offering newfound hope patients grappling advanced that harbor particular biomarkers. In this comprehensive review, authors delve into expansive landscape tissue-agnostic targets drugs, shedding light rationale underpinning approach, hurdles it faces, presently approved therapies, voices from patient advocacy perspective, tantalizing prospects horizon. is welcome advance transcends boundaries histology location provide personalized options.
Язык: Английский
Процитировано
25
Springer eBooks, Год журнала: 2024, Номер unknown, С. 1461 - 1498
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
24